Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Sarepta Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

70 comunicati stampa

Guarda tutti i comunicati
27/02/2026
Appalti e gare
Università
Biotecnologia
Scuola/Istruzione
Igiene alimentare
Salute
Farmaceutica
Politica Locale
Scienza
Vetrine/Shopping
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
26/02/2026
Eventi
Industria
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Sanità
Farmaceutica
Salute
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/02/2026
Industria
Scienza
Cardiologia
Biotecnologia
Salute
Igiene alimentare
Medicina - Varie
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/02/2026
Web e Social Network
Eventi
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/02/2026
Salute
Igiene alimentare
Biotecnologia
Scienza
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/02/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
26/01/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Telefonia e Varie
Industria
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/01/2026
Salute
Igiene alimentare
Biotecnologia
Scienza
Farmaceutica
Web e Social Network
Telefonia e Varie
Eventi
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Salute
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Eventi
Mercato azionario
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0